Introduction {#s1}
============

Frontotemporal lobar degeneration (FTLD) is a pathological process that represents one of the main causes of dementia (Cardarelli et al., [@B7]), after *Alzheimer\'s* Disease (AD), accounting for 5--10% of all dementias and is characterized by atrophy in the frontal and temporal lobes of the brain (Seltman and Matthews, [@B58]). At clinical level, FTLD patients manifest personality and social behavior changes and, often gradual and progressive language dysfunction (McKhann et al., [@B44]). Approximately 15% of patients also develop symptoms of motor neuron dysfunction. Pathologically, around 40% of FTLD patients present with inclusions of hyperphosphorylated microtubule-associated protein tau (FTLD-tau; Morris et al., [@B49]), whereas the most FTLD patients shows ubiquitin-positive inclusions (FTLD-U) constituted mainly by TAR DNA-binding protein 43 (TDP-43; Neumann et al., [@B51]). Genetically, several genes are described in association to the disease, including microtubule associated protein tau (*MAPT*), progranulin (*GRN*), and *C9ORF72*. Rare mutations were also found in genes coding charged multivesicular body protein 2B (*CHMP2B*), the valosin-containing protein (*VCP*), TAR DNA-binding protein (*TARDBP*), and *FUS* (Sieben et al., [@B61]). The genetic heterogeneity is further complicated by possible different clinical manifestations within a single mutation and even within individual families, suggesting the involvement of post-transcriptional regulation mechanisms such as microRNAs (miRNAs).

miRNA biogenesis and functions {#s2}
==============================

Aberrant RNA processing can cause or exacerbate neurodegenerative diseases *via* many mechanisms. Less than 5% of total cellular RNA is messenger RNA coding for proteins, and the other 95% is non-coding RNAs that has been shown to have a profound impact on gene expression regulation and also on other neurochemical processes, and to be implicated as complexity multipliers in both normal and abnormal conditions of the human central nervous system (Nelson and Keller, [@B50]; Peterson et al., [@B55]; Rapoport and Nelson, [@B57]). miRNAs are members of non-coding RNAs and silence mRNA molecules via base-pairing with their complementary sequences (Fire et al., [@B15]). miRNAs are involved in all development and pathologic processes targeting protein-coding transcripts mainly in the 3′UTR (Lytle et al., [@B41]). The biogenesis of miRNAs is controlled at temporal and spatial level. miRNAs are composed of \~22 nucleotides and produced by two RNase III proteins: Drosha and Dicer. Indeed, after the transcription, primary miRNAs (pri-miRNA) undergo to following steps: Drosha cleaves at the base of a stem to generate \~60--100 nt hairpin precursor miRNAs (pre-miRNA; Lee et al., [@B37]; Denli et al., [@B12]); then, pre-miRNA is carried into the cytoplasm by exportin 5 (Exp5) and once in the cytoplasm, it is processed by Dicer, arising a mature duplex of miRNAs long about 22 bp (Cullen, [@B9]; Winter and Diederichs, [@B71]).

FTLD pathogenically-related proteins and miRNA biogenesis
---------------------------------------------------------

TDP-43, one of FTLD pathogenically-related proteins, binds both DNA and RNA and has multiple functions in mRNA metabolism contributing to transcriptional repression, pre-mRNA splicing and translational regulation (Buratti et al., [@B6]; Wang et al., [@B67]; Da Cruz and Cleveland, [@B10]). Interestingly, TDP-43 has been found in a macromolecular complex containing Drosha and Dicer (Gregory et al., [@B21]; Kawahara and Mieda-Sato, [@B29]). In addition, TDP-43 binds directly to a subset of pri-miRNAs to promoting the production of pre-miRNAs (Kawahara and Mieda-Sato, [@B29]). FUS, another FTLD pathogenically-related protein, is a highly conserved RNA/DNA binding protein, as well. It participates to regulation of gene expression and RNA processing to the DNA damage response (Wang et al., [@B70]). FUS was also found in the macromolecular complex containing Drosha (Kawahara and Mieda-Sato, [@B29]) and binding to pri-miRNAs for miRNA processing (Morlando et al., [@B48]).

miRNAs in the nervous system {#s3}
============================

miRNAs are abundant in the nervous system and show a brain-specific expression profile correlated to the expression of their targets. In fact, as suggested by several microarray studies, the brain expresses a large number of miRNAs that participate in nervous system physiology (Lagos-Quintana et al., [@B33]; Miska et al., [@B47]; Lim et al., [@B39]; Manakov et al., [@B43]). In particular, they have key roles in the regulation of different biological functions, as important mediators of plasticity and neurogenesis, in which they channelize cellular physiology toward neuronal differentiation. Moreover, they regulate the proliferation and self-renewal of neural stem cells indirectly influencing neurogenesis (Stappert et al., [@B63]). miRNAs are dysregulated in several neurodegenerative diseases that share a final common pathway of neuronal cell death. Neurodegeneration includes complex pathogenic mechanisms; above all, aging is the main risk factor, but other common characteristics exist among these pathologies, such as neuroinflammation, protein aggregation, and mitochondrial dysfunction. Profiling analysis of miRNA expression in several nervous system disorders identified signatures correlated with the diagnosis, progression and prognosis of diseases, and treatment monitoring (Shafi et al., [@B59]; Langbaum et al., [@B34]). The role of specific miRNAs in a disease has been established in just a few cases and most of the mechanistic data originates from invertebrate model systems. In any case, the importance of miRNAs in neurodegenerative disorders and their emerging role in AD, Parkinson\'s disease, Huntington\'s disease, and Amyotrophic lateral sclerosis is becoming more and more evident. (Kim et al., [@B30]; Johnson et al., [@B28]; Wang et al., [@B68]; Nunez-Iglesias et al., [@B53]; Lukiw et al., [@B40]; Grasso et al., [@B20]). In AD patients, for example, profiling studies highlighted dramatic changes in several miRNAs (i.e., miR-29 cluster, miR-107, miR-9, miR-125b, and miR-128; Delay et al., [@B11]). Although these alterations under pathological conditions should be interpreted with caution, they support the idea that dysregulation of miRNAs is a common mechanism in neurodegenerative diseases. Consequently, the study of miRNAs is a novel tool to understanding these diseases and possibly find therapeutic targets. For a complete coverage of the roles of miRNAs in other neurodegenerative diseases, we suggest some recent review articles (Gascon and Gao, [@B17]; Maciotta et al., [@B42]; Grasso et al., [@B19]; Femminella et al., [@B13]).

miRNAs and FTLD {#s4}
===============

In the last years, several studies have been addressed to understand the role of miRNAs in the pathophysiology of FTLD. Two approaches are frequently used to study the involvement of miRNAs in the pathology. The first is based on a global approach of miRNA profiling with subsequent validation by RT-qPCR. The second approach is based on the analysis of miRNAs showing a direct connection with the disease.

miRNAs expression profiling
---------------------------

Kocerha and colleagues decribed an expression profiling study to identify miRNAs responsive to *GRN* haploinsufficiency. They analyzed the global miRNAs in the frontal cortex of 8 FTLD-TDP patients with *GRN* mutations and compared them to a population of 32 FTLD-TDP patients with no apparent genetic abnormalities (Kocerha et al., [@B32]). Using TaqMan Array Human MicroRNA, they identified 20 miRNAs differentially expressed (*P* \< 0.05) in frontal cortex. Moreover, a validation study by RT-qPCR analyzes confirmed a differential expression for 9 of the 20 miRNAs in frontal cortex (miR-33a^\*^, let7i^\*^, miR-516a-3p, miR-548b-5p, miR-548c-5p, miR-565, miR-571, miR-572, and miR-922). Since these data have not been functionally validated, the mechanism by which PGRN haploinsufficiency in FTLD patients leads to altered expression of these miRNAs is currently unclear and requires future studies. Moreover, little or nothing has been studied about the role of these miRNAs in brain or other neurodegenerative diseases. For example, miR-922 is described as a promoter of tau phosphorylation by down-regulating ubiquitin carboxy-terminal hydrolase L1 expression in AD (Zhao et al., [@B74]), but other studies are needed to explain their role on neurological disease pathogenesis.

An expression profiling study was also performed by RNA deep sequencing in miRNAs derived from well-characterized brain samples originated from autopsy series at the University of Kentucky AD Center (UK ADC; Hébert et al., [@B24]). They analyzed temporal neocortex gray matter samples of five FTLD cases, as well as non-demented controls (*n* = 2), AD (*n* = 5), dementia with Lewy bodies (*n* = 4), hippocampal sclerosis in aging (*n* = 4). From a total of 795 miRNAs expressed in the human brain, they identified 31 human miRNAs differently expressed. The validation study by miRNA RT-qPCR analysis reported a down-regulation of miR-132-3p in FTLD cases. A similar result was obtained by the same authors in AD patients, as well suggesting that this miRNA could have a more general function in neurodegeneration than a direct role in specific subtypes of pathology. Recently, this miRNA was found participating to a post-transcriptional mechanism that increases intracellular levels of PGRN, as reported below.

miRNA-132, miR-29b, and miR-659 regulate GRN expression
-------------------------------------------------------

Progranulin (PGRN), encoded by the *GRN* gene, is a widely expressed protein involved in the regulation of cell growth and cell cycle progression (Bateman et al., [@B4]; He and Bateman, [@B25]). Mutations in the *GRN* gene are linked with FTLD (Baker et al., [@B3]). Recent findings suggest that *GRN* is under the control of miRNAs (Table [1](#T1){ref-type="table"}).

###### 

**miRNAs involved in FTLD**.

  **Alterated miRNAs**    **Regulation**                                                               **Target genes**               **Related pathway to FTD**                                                      **References**
  ----------------------- ---------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------- ---------------------------------------------------
  miR-132/212 Cluster     Downregulated in FTLD-TDP brains                                             TMEM106B                       Regulating PGRN levels                                                          Chen-Plotkin et al., [@B8]; Hébert et al., [@B24]
  miR-107                 Downregulated in mice with cortical traumatic brain injury                   GRN                            Regulating PGRN levels                                                          Wang et al., [@B69]
  miR-659                 Genetic variant located in the 3′-UTR of GRN within a miR-659 binding site   GRN                            Genetic variability in binding-site of miR-659 can increase the risk for FTLD   Rademakers et al., [@B56]
  miR-29b                 --                                                                           GRN                            Regulating PGRN levels                                                          Jiao et al., [@B27]
  miR-9 and pri-miR-9-2   Downregulated in patient neurons                                             Neuronal specification genes   Neuronal toxicity                                                               Zhang et al., [@B73]
                          Downregulated in TDP-43 mutants of Drosophila                                                                                                                                               Li et al., [@B38]
  miR-124                 Downregulated in a FTD mouse model                                           AMPAR                          Regulating social behavior                                                      Gascon et al., [@B18]

### miR-132 and miR-132-3p cluster

miR-132 down-regulation was also recently observed in another cohort of FTLD-TDP brains (Baker et al., [@B3]), thus confirming the data from Hebert and colleagues (He and Bateman, [@B25]). This miRNA is a member of the miR-132 cluster (miR-132, miR-132^\*^, and miR-212). miR-132 and miR-212 target *TMEM106B* through two specific sites in the *TMEM106B* 3′UTR. Chen Plotkin and colleagues, having observed increased *TMEM106B* expression in FTLD-TDP, supposed a possible upstream role for miR-132/212. Effectively, they showed first of all that miR-132 and miR-212 normally repress *TMEM106B* and then that they are decreased in FTLD-TDP. Moreover, an involvement of *TMEM106B* gene on *GRN* expression was also observed; in details, this gene was found to be linked to FTLD-TDP (Van Deerlin et al., [@B64]; Van der Zee et al., [@B65]) and *TMEM106B* risk genotypes correlated with decreased plasma progranulin levels (Finch et al., [@B14]). Overall, these results suggest a model in which decreased levels of miR-132/212 carry out to a higher *TMEM106B* expression leading to increased *TMEM106B* expression and to endosomal-lysosomal dysfunction, which may, in turn, further increase the levels of TMEM106B, and perturb PGRN pathways, thereby increasing the risk of developing FTLD-TDP (Chen-Plotkin et al., [@B8]).

Further evidence linking miR-132 to FTLD are the reports addressing its role to the regulate splicing process of the microtubule associated protein tau gene (Smith et al., [@B62]; Hebert et al., [@B23]) and an involvement in cognitive function in experimental models including neuronal/synaptic integrity and the brain\'s response to stressors (O\'Neill, [@B54]; Mellios et al., [@B45]; Miller et al., [@B46]; Wanet et al., [@B66]; Shaltiel et al., [@B60]; Bicker et al., [@B5]).

### miR-107

A miRNA assay (RIP-Chip) in neuron-like human cell lines showed that *GRN* is a strong target for miR-107 (Wang et al., [@B69]). This miRNA recognizes mainly sequence elements in the open reading frame rather than the 3′UTR of *GRN* mRNA; these sequences are highly conserved among vertebrate species. Wang and colleagues described a down-regulation of miR-107 in a mouse model of traumatic brain injury, speculating that this miRNA plays a role in modulating neuronal repair and regeneration in the mammalian brain through molecular regulation of *GRN* and other mRNA targets. Moreover, they described that miR-107 has also been involved in AD. In addition, Noren Hooten et al. compared miRNA expression of blood mononuclear cells in young individuals related to old individuals by RT-qPCR analysis to test possible aging-related differences and found that miR-107 was significantly decreased in aged individuals (Noren Hooten et al., [@B52]). Taken to in consideration this evidence, it would be interesting to study the existence of a possible link between miR-107 expression and FTLD.

### miR-659

Another miRNA regulating *GRN* expression is miR-659. Rademakers and colleagues described an allelic variant associated to FTLD (Rademakers et al., [@B56]) located in the 3′UTR of *GRN* corresponding to a predicted binding site for miR-659. They described that genotype TT for SNP rs5848 was associated to FTLD with a 3.2-fold increased risk to develop the pathology suggesting that a genetic variant in a miRNA binding-site can influence the risk for FTLD. They further demonstrate that miR-659 can regulate GRN expression *in vitro*, with miR-659 binding more efficiently to the high risk T allele of rs5848. In order to evaluate the possibility that rs5848 variant is involved in *GRN* regulation in patients, they analyzed its expression in FTLD patient brains revealing an association between *GRN* lower levels and the TT genotype. However, other studies are needed to verify a possible role of miR-659 in the brain and particularly in FTLD.

### miR-29b

Another binding site in the 3′UTR of *GRN* mRNA was identified for miR-29b. Indeed, Jiao and colleagues demonstrated that miR-29b interacts directly with the *GRN* 3′UTR, regulating the *GRN* expression (Jiao et al., [@B27]). MiR-29b has a role in neurodevelopment and reach the highest level in adult mouse brain. Moreover, it is differentially expressed in AD patients (Hebert et al., [@B22]), even if to date we do not have evidence about a regulatory role of this miRNA in FTLD patients. Thus, several miRNAs may contribute to the pathogenesis of FTLD linked to progranulin deficiency.

miR-9 and TDP43
---------------

As previously reported, TDP-43 has two RNA recognition motifs and is involved in several roles of RNA metabolism (Da Cruz and Cleveland, [@B10]; Lee et al., [@B36]). Among these, TDP43 has been associated to miRNA processing; miR-9 is one of these and is described as an evolutively conserved miRNA, brain-specific and implicated in some neurodegenerative diseases. A work published by Zhang and colleagues described a down-regulation of miR-9 in iPSC-derived neurons (iPSC: induced pluripotent stem cells) of FTD/ALS patients with *TDP-43* mutations; they explained their results as an a effect of decreased TDP-43 expression revealed in these neurons (Zhang et al., [@B73]). Moreover, they found that levels of both pre-miR-9-2 and pri-miR-9-2 were also reduced, suggesting that miRNA decrease did not seem to be due to a defect in the miRNA-processing pathway.

Recently, a work on mutant *TDP-43* showed an involvement in FTLD of Drosha protein, one of the most important miRNA processing molecules involved in the biogenesis of miRNAs. In this study Drosha increased in correlation with a TDP-43 activation in Neuro 2A cells, leading to hypothesize that a mutant *TDP-43* in FTLD-U, associated with Drosha instability, can induce neuronal toxicity (Kim et al., [@B31]). Also in Drosophila, TDP-43 seems to regulate miR-9a levels by interacting with pri-miR-9a and likely promoting its stability (Li et al., [@B38]).

miR-124 and social behavioral deficits
--------------------------------------

miR-124 is one of most abundant miRNAs in the brain known to be involved in neuronal development. (Gao, [@B16]). Furthermore, it seems to have a role also in neurodegeneration and in regulating social behavior in FTLD models. Gascon and colleagues studied a new mouse model of FTLD exhibiting deficits in sociability (Gascon et al., [@B18]). They found that miR-124 is down-regulated in this model causing a dysregulation in AMPA receptor (AMPAR) composition and a selective impairment in sociability. Moreover, they examined miR-124 and AMPAR expression in subjects with FTLD, focusing on the frontal cortex in the subset of cases with bvFTD, whose clinical presentation is closest to the phenotypes observed in their mouse model. They found a decrease in miR-124 expression and a concomitant up-regulation of two AMPAR subunits in the frontal cortex of bvFTD patients compared with age-matched controls. Furthermore, they studied miR-124 and AMPARs in established iPSC lines derived from subjects with bvFTD (Almeida et al., [@B2], [@B1]), in which the expression of miR-124 and AMPARs in 8-week-old neurons were reduced and some AMPAR subunit mRNAs upregulated.

Increasing evidences support the presence of common miRNAs differentially expressed in several neurodegenerative diseases. For example, miR-132, decreased in FTLD brains, is emerging as gradually down-regulated during AD at early, mid, and late stages of disease and showing its important role in the maintenance of brain integrity (Lau et al., [@B35]). Another miRNA regulated in both FTLD and AD is miR-107 that decreases in the temporal cortex of LOAD patients; in luciferase assays, it showed a functional interaction with 3′UTR region of BACE1, a protease involved in the cleavage of APP for the generation of amyloid-beta (Wang et al., [@B68]). miR-107 also controls the expression of other proteins relevant to AD pathology, such as cofilin (Yao et al., [@B72]), an actin-binding protein that accumulates in cytoplasmic inclusions. Also miR-29b was found to be alterated in AD and interacting with BACE, as described by Hebert and colleagues (Hebert et al., [@B22]). Moreover, it was hypothesized that deregulation of miR-29b in the brain was associated to the increase of apoptotic markers in AD, since miR-29b has been shown to target a family of pro-apoptotic regulators (Delay et al., [@B11]). Then, it could be conceivable the existence of common miRNAs pathways involved in the molecular mechanisms of some neurodegenerative diseases.

Final remarks {#s5}
=============

In the last years, miRNAs studies are becoming more and more powerful to understand molecular mechanisms of complex disorders, such as dementias because they can regulate in fine-manner the pathways involved in the onset and progression of the disease and represent molecular tools as biomarkers and new therapeutic targets. Recent literature prompts that miRNAs could have an upstream and/or downstream role in the frontotemporal pathology to regulate a cascade of events leading to the neurodegeneration.

The studies mentioned in this mini-review provide interesting clues about miRNAs involvement in the pathology, and even if rather fragmentary, they could be further deepened by using high-throughput techniques such as small-RNAseq possibly not only in patients, but also in cellular and animal models. Several advances have been performed on the developing of FTLD models, such as tau and TDP-43 transgenic mice reproducing some features of FTLD, such as reduced survival, fragmentation and insolubility of protein aggregates, gliosis, and neuronal loss. Moreover, iPSCs are likely to become a standard in the field of neurodegenerative diseases, complementing, but not replacing, genetic animal models (Ittner et al., [@B26]). Methodologies used for miRNAs in FTLD ranged from Northern blotting to microarrays, but further advances could arrive from small RNASeq sequencing useful to detect small RNAs from very low amounts of starting biological material and discovery novel miRNAs expressed in a specific pathology.

Despite last advances on molecular and pathological bases in FTLD, the pathology remains still orphan for disease-modifying therapies. The identification of disease modulating factors will in turn ameliorate the knowledge of FTLD molecular pathways opening, in the future, to new therapeutic strategies.
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